Artivion (NYSE:AORT) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Artivion (NYSE:AORT) in a research report sent to investors on Tuesday,Benzinga reports. Needham & Company LLC currently has a $34.00 target price on the stock.

A number of other brokerages have also issued reports on AORT. Oppenheimer raised their price target on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a report on Tuesday, December 10th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artivion presently has an average rating of “Buy” and an average price target of $31.80.

Artivion Trading Up 1.3 %

Shares of Artivion stock opened at $31.04 on Tuesday. Artivion has a fifty-two week low of $16.48 and a fifty-two week high of $32.33. The business’s fifty day moving average is $29.32 and its two-hundred day moving average is $27.39. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The firm has a market cap of $1.30 billion, a PE ratio of -1,551.75 and a beta of 1.74.

Insiders Place Their Bets

In related news, CAO Amy Horton sold 4,329 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the sale, the chief accounting officer now owns 135,660 shares of the company’s stock, valued at approximately $4,023,675.60. This represents a 3.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Andrew M. Green sold 7,618 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total transaction of $228,540.00. Following the completion of the transaction, the vice president now directly owns 33,503 shares in the company, valued at approximately $1,005,090. This represents a 18.53 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 20,017 shares of company stock worth $600,007 over the last three months. 8.10% of the stock is owned by insiders.

Institutional Trading of Artivion

Hedge funds have recently made changes to their positions in the company. FMR LLC grew its holdings in Artivion by 28.0% during the 3rd quarter. FMR LLC now owns 115,184 shares of the company’s stock valued at $3,066,000 after purchasing an additional 25,176 shares in the last quarter. Barclays PLC boosted its position in Artivion by 346.3% in the 3rd quarter. Barclays PLC now owns 70,877 shares of the company’s stock valued at $1,888,000 after buying an additional 54,996 shares during the last quarter. Lord Abbett & CO. LLC acquired a new stake in shares of Artivion during the third quarter valued at about $5,798,000. JPMorgan Chase & Co. increased its position in shares of Artivion by 394.9% during the third quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock worth $2,606,000 after acquiring an additional 78,120 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Artivion by 58.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock worth $9,074,000 after acquiring an additional 125,668 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.